Laboratory Medicine banner
HomeFaculty › Amalia Magaret, PhD

Amalia Magaret, PhD

photo Dr. Amalia Magaret

Research Professor, Virology
Joint Associate Member, Program in Biostatistics and VIDD, Fred Hutchinson Cancer Research Center

Contact Information

Virology Research Clinic
Harborview Medical Center
Box 359928
325 9th Avenue
Seattle, WA 98104-2499
Tel: 206.520.4316
Fax: 206.520.4371

Education and Training

  • BS in Chemistry/Math, University of Notre Dame, 1992
  • MS in Applied Statistics, Western Michigan University, 1997
  • PhD in Biostatistics, University of Washington, 2001
  • Statistician, Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, 1998-00
  • Statistician and Consultant, University of Washington research projects at Kenyatta National Hospital, Nairobi, Kenya, 1998-05
  • Pre-Doctoral Fellow, Center for AIDS/STD Research, Seattle, WA, 2000-01
  • Post-Doctoral Research Associate, SCHARP, Fred Hutchinson Cancer Research Center, Seattle, WA, 2002-03
  • Clinical Research Associate, Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, WA, 2003-04

Research Interests

  • Herpesvirus infections
  • Statistical methods related to shedding and mismeasured outcomes

Current Research

  • P01 AI-30731-22 (A. Wald) 4/1/2008- 3/31/13 NIH / NIAID
    Clinical Epidemiology & Pathogenesis of Asymptomatic Genital Herpes (Core C)
    This Core of the P01 grant has four specific aims: 1) assist in the planning of experiments, including sample size calculations and study design, 2) coordinate data collection, verification and management, in collaboration with laboratories and other data collection sources, 3) perform statistical analyses and assist in interpretation of results, developing or adapting new methodology as appropriate and 4) develop new statistical methodologies as appropriate.
    Role: Core Leader; Statistical Core
  • K24 AI 071113-06 (A. Wald) 6/1/2011-5/31/2016 NIH / NIAID
    Clinical Research in HSV Infections
    The goal of this mid-career mentor award is to expand training in clinical virology, with focus on HSV-2 infections, at the University of Washington, through collaborations with several ongoing training programs. The proposed projects focus on populations that suffer disproportionately from HSV-2 infections: pregnant women and HIV-infected persons.
  • R01AI091701-01A1 (C. Posavad) 5/15/2011 –04/30/2016 NIH / NIAID
    T Cell Immunity to HSV-2 in Immune Seronegative Subjects
    The goal of this proposal is to characterize the immune response to herpes in these subjects in order to develop vaccine strategies to prevent herpes.
  • R01 AI042528-15 (L. Corey) 4/1/2012-3/31/2017 NIH / NIAID
    Cytotoxic T Cell Response to HSV in HIV Infected Persons
    To further study the immune surveillance function of these cells and how they contain viral reactivation, a key concept that will lay the groundwork for better design and development of HSV-2 vaccines.
  • R01 AI094019-01A1 (D. Koelle) 9/1/2011-8/31/2016 NIH/NIAID
    Genomic systems approach to measure HSV-1-specific T-cell dominance in humans
    To determine immunodominant CD8 and CD4 antigens in HSV-1 suitable for vaccine development.

Selected Publications

  1. Magaret AS. 2008. Incorporating validation subsets into discrete proportional hazards models for mismeasured outcomes. Statistics in Medicine;27(26):5456-70.
  2. Magaret AS, Johnston C, Wald A. 2009. Use of the designation "shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling. STI;85(4):270-5.5.
  3. Magaret AS, Stanaway J. Sample size for a binomial rate with autocorrelation. Stat Comm Infect Dis;3(1):Article 8. DOI: 10.2202/1948-4690.1036.
  4. Tronstein E, Johnston C, Huang ML, Selke S, Magaret A, Warren T, Corey L, Wald A. 2011. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA;305(14):1441-9.
  5. Johnston C, Saracino M, Kuntz S, Magaret AS, Selke S, Huang ML, Schiffer JT, Koelle DM, Corey L, and Wald A. 2012. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet;379(9816):641-7.

Honors and Awards

  • ASA Award for Outstanding Achievement, Western Michigan University, 1997
  • Outstanding Student in Biostatistics, SPHCM, University of Washington, 2001

Last updated: 07/01/2016

HomeFaculty › Amalia Magaret, PhD

Return to Top